

Resource Summary Report

Generated by SPARC SAWG on Sep 5, 2026

Phospho-Rb (Ser780) (D59B7) Rabbit mAb

RRID:AB_10950972

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 8180, RRID:AB_10950972

Antibody Information

URL: http://antibodyregistry.org/AB_10950972

Proper Citation: Cell Signaling Technology Cat# 8180, RRID:AB_10950972

Target Antigen: Phospho-Rb (Ser780) (D59B7) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP

Antibody Name: Phospho-Rb (Ser780) (D59B7) Rabbit mAb

Description: This monoclonal targets Phospho-Rb (Ser780) (D59B7) Rabbit mAb

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_10950972

Vendor: Cell Signaling Technology

Catalog Number: 8180

Record Creation Time: 20231110T063035+0000

Record Last Update: 20260829T010055+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-Rb (Ser780) (D59B7) Rabbit mAb.

No alerts have been found for Phospho-Rb (Ser780) (D59B7) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Han S, et al. (2026) Celecoxib potentiates ribociclib-induced apoptosis and anti-tumor activity by co-targeting COX-2/NF- κ B and PI3K/AKT/mTOR pathways in hormone receptor-positive/HER2-negative breast cancer. *Apoptosis : an international journal on programmed cell death*, 31(5).

Hawsawi O, et al. (2025) Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth. *Cell reports. Medicine*, 6(1), 101890.

Tang J, et al. (2025) Targeting N-Myc in neuroblastoma with selective Aurora kinase A degraders. *Cell chemical biology*, 32(2), 352.

Ren L, et al. (2025) Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. *Cancer cell*.

Hu X, et al. (2025) The transcription factor MEF2C restrains microglial overactivation by inhibiting kinase CDK2. *Immunity*, 58(4), 946.

Goerg A, et al. (2025) Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition. *BMC cancer*, 25(1), 978.

Chen A, et al. (2024) PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. *Molecular cancer therapeutics*, 23(10), 1494.

Jochems F, et al. (2024) Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state. *Cell death and differentiation*.

Lachiondo-Ortega S, et al. (2024) SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer. *Cell reports*, 43(3), 113924.

Lu K, et al. (2023) Multiple cullin-associated E3 ligases regulate cyclin D1 protein stability. *eLife*, 12.

Randic T, et al. (2023) Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response. *Cell reports*, 42(7), 112696.

Ouyang H, et al. (2023) p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor-suppressor function mediated by p190A RhoGAP. *Cell reports*, 42(12), 113486.

Pan M, et al. (2023) UTP18-mediated p21 mRNA instability drives adenoma-carcinoma progression in colorectal cancer. *Cell reports*, 42(5), 112423.

Gou X, et al. (2023) Kinome reprogramming is a targetable vulnerability in ESR1 fusion-driven breast cancer. *Cancer research*.

Shagisultanova E, et al. (2022) Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. *Molecular cancer therapeutics*, 21(1), 48.

Sanidas I, et al. (2022) Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression. *Molecular cell*, 82(18), 3333.

Emdal KB, et al. (2022) Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance. *Cell reports*, 40(6), 111177.

Jochems F, et al. (2021) The Cancer SENESCopedia: A delineation of cancer cell senescence. *Cell reports*, 36(4), 109441.

Klomp JE, et al. (2021) CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. *Cell reports*, 37(9), 110060.

Romero-Pozuelo J, et al. (2020) Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1. *Cell reports*, 31(2), 107504.